Trial details
A Phase 3 Trial of Fianlimab (anti-LAG-3) and Cemiplimab versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-risk Melanoma
To find out more about this trial and your cancer treatment options, please speak with your doctor.
Trial short name: ADJ LAG3
Official title: A Phase 3 Trial of Fianlimab (anti-LAG-3) and Cemiplimab versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-risk Melanoma
Principal Investigator: Dr. Teresa Petrella
Cancer type: Melanoma
Cancer location: Melanoma
Disease stage: Early Cancer
Trial phase: Phase 3
Intervention:
Registration #:
NCT05608291 
Contact e-mail: cancerclinicaltrials@sunnybrook.ca
Trial description:
The primary objective of the study is To demonstrate superiority of fianlimab + cemiplimab compared to pembrolizumab, as measured by relapse free survival (RFS)
The secondary objectives of the study are:
To demonstrate superiority of fianlimab + cemiplimab compared to pembrolizumab, as measured by overall survival (OS)
To demonstrate superiority of fianlimab + cemiplimab compared to pembrolizumab, as measured by melanoma specific survival (MSS)
To evaluate whether post-operative adjuvant therapy improves distant metastasis-free survival (DMFS), in stage IIC or III patients receiving fianlimab + cemiplimab compared to pembrolizumab
To assess impact of fianlimab + cemiplimab on quality of life as compared to pembrolizumab in adults
To assess safety and tolerability of fianlimab + cemiplimab compared to pembrolizumab
To characterize pharmacokinetics (PK) of fianlimab + cemiplimab using sparse PK sampling in patients 12 years of age and older
To assess immunogenicity of fianlimab and against cemiplimab
Key Inclusion Criteria: 1. All patients must be either stage IIC, III, or stage IV per American Joint Committee on Cancer (AJCC) 8th edition and have histologically confirmed melanoma that is completely surgically resected in order to be eligible as defined by the protocol 2. Complete surgical resection must be performed within 12 weeks prior to randomization, and enrollment may occur only after satisfactory wound healing from the surgery 3. All patients must have disease-free status documented by a complete physical examination and imaging studies within 4 weeks prior to randomization, as described in the protocol Key Exclusion Criteria: 1. Uveal melanoma 2. Any evidence of residual disease after surgery by imaging, pathology, or cytology. 3. Ongoing or recent (within 2 years) evidence of clinically significant autoimmune disease that required systemic treatment with immunosuppressive agents 4. Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C (HCV) infection; or diagnosis of immunodeficiency that is related to, or results in chronic infection, as described in the protocol 5. Another malignancy that is currently progressing or that required active treatment in the past 5 years, as described in the protocol 6. Adolescent patients (≥12 to <18 years old) with body weight <40 kg
